Liver	B:C0023884
-	O
specific	O
mono-	O
unsaturated	I:C0015683
fatty	I:C0015683
acid	I:C0015683
synthase	I:C0015683
-	I:C0015683
1	I:C0015683
inhibitor	O
for	O
anti-hepatitis	O
C	I:C0243095
treatment	O
.	O

Liver	O
-	O
specific	O
mono-	B:C0015683
unsaturated	I:C0015683
fatty	I:C0015683
acid	I:C0015683
synthase	I:C0015683
-	I:C0015683
1	I:C0015683
inhibitor	O
for	O
anti-hepatitis	O
C	I:C0243095
treatment	O
.	O

Liver	O
-	O
specific	O
mono-	O
unsaturated	I:C0015683
fatty	I:C0015683
acid	I:C0015683
synthase	I:C0015683
-	I:C0015683
1	I:C0015683
inhibitor	B:C0014432
for	O
anti-hepatitis	O
C	I:C0243095
treatment	O
.	O

Liver	O
-	O
specific	O
mono-	O
unsaturated	I:C0015683
fatty	I:C0015683
acid	I:C0015683
synthase	I:C0015683
-	I:C0015683
1	I:C0015683
inhibitor	O
for	O
anti-hepatitis	B:C0243095
C	I:C0243095
treatment	O
.	O

Liver	O
-	O
specific	O
mono-	O
unsaturated	I:C0015683
fatty	I:C0015683
acid	I:C0015683
synthase	I:C0015683
-	I:C0015683
1	I:C0015683
inhibitor	O
for	O
anti-hepatitis	O
C	I:C0243095
treatment	B:C0087111
.	O

Recently	O
,	O
direct	O
antiviral	B:C0003451
agents	I:C0003451
against	O
hepatitis	O
C	I:C4288963
virus	I:C4288963
(	I:C4288963
HCV	I:C4288963
)	I:C4288963
infection	I:C4288963
have	O
been	O
developed	O
as	O
highly	O
effective	O
anti-HCV	O
drugs	O
.	O

Recently	O
,	O
direct	O
antiviral	O
agents	I:C0003451
against	O
hepatitis	B:C4288963
C	I:C4288963
virus	I:C4288963
(	I:C4288963
HCV	I:C4288963
)	I:C4288963
infection	I:C4288963
have	O
been	O
developed	O
as	O
highly	O
effective	O
anti-HCV	O
drugs	O
.	O

However	O
,	O
the	O
appearance	O
of	O
resistant	O
viruses	B:C0042776
against	O
direct	O
anti-viral	O
agents	I:C0003451
is	O
an	O
unsolved	O
problem	O
.	O

However	O
,	O
the	O
appearance	O
of	O
resistant	O
viruses	O
against	O
direct	O
anti-viral	B:C0003451
agents	I:C0003451
is	O
an	O
unsolved	O
problem	O
.	O

However	O
,	O
the	O
appearance	O
of	O
resistant	O
viruses	O
against	O
direct	O
anti-viral	O
agents	I:C0003451
is	O
an	O
unsolved	O
problem	B:C0033213
.	O

One	O
of	O
the	O
strategies	O
considered	O
to	O
suppress	O
the	O
emergence	O
of	O
the	O
drug	B:C0013203
-	I:C0013203
resistant	I:C0013203
viruses	O
is	O
to	O
use	O
drugs	O
inhibiting	O
the	O
host	O
factor	O
,	O
which	O
contributes	O
to	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
proliferation	O
,	O
in	O
combination	O
with	O
direct	O
anti-viral	O
agents	I:C0003451
.	O

One	O
of	O
the	O
strategies	O
considered	O
to	O
suppress	O
the	O
emergence	O
of	O
the	O
drug	O
-	I:C0013203
resistant	I:C0013203
viruses	B:C0042776
is	O
to	O
use	O
drugs	O
inhibiting	O
the	O
host	O
factor	O
,	O
which	O
contributes	O
to	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
proliferation	O
,	O
in	O
combination	O
with	O
direct	O
anti-viral	O
agents	I:C0003451
.	O

One	O
of	O
the	O
strategies	O
considered	O
to	O
suppress	O
the	O
emergence	O
of	O
the	O
drug	O
-	I:C0013203
resistant	I:C0013203
viruses	O
is	O
to	O
use	O
drugs	B:C1254351
inhibiting	O
the	O
host	O
factor	O
,	O
which	O
contributes	O
to	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
proliferation	O
,	O
in	O
combination	O
with	O
direct	O
anti-viral	O
agents	I:C0003451
.	O

One	O
of	O
the	O
strategies	O
considered	O
to	O
suppress	O
the	O
emergence	O
of	O
the	O
drug	O
-	I:C0013203
resistant	I:C0013203
viruses	O
is	O
to	O
use	O
drugs	O
inhibiting	O
the	O
host	O
factor	O
,	O
which	O
contributes	O
to	O
hepatitis	B:C0220847
C	I:C0220847
virus	I:C0220847
proliferation	O
,	O
in	O
combination	O
with	O
direct	O
anti-viral	O
agents	I:C0003451
.	O

One	O
of	O
the	O
strategies	O
considered	O
to	O
suppress	O
the	O
emergence	O
of	O
the	O
drug	O
-	I:C0013203
resistant	I:C0013203
viruses	O
is	O
to	O
use	O
drugs	O
inhibiting	O
the	O
host	O
factor	O
,	O
which	O
contributes	O
to	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
proliferation	O
,	O
in	O
combination	O
with	O
direct	O
anti-viral	B:C0003451
agents	I:C0003451
.	O

The	O
replication	B:C1167179
complex	I:C1167179
was	O
reported	O
to	O
be	O
present	O
in	O
the	O
membranous	O
compartment	O
in	O
the	O
cells	O
.	O

The	O
replication	O
complex	I:C1167179
was	O
reported	O
to	O
be	O
present	B:C0150312
in	O
the	O
membranous	O
compartment	O
in	O
the	O
cells	O
.	O

The	O
replication	O
complex	I:C1167179
was	O
reported	O
to	O
be	O
present	O
in	O
the	O
membranous	O
compartment	B:C1948049
in	O
the	O
cells	O
.	O

The	O
replication	O
complex	I:C1167179
was	O
reported	O
to	O
be	O
present	O
in	O
the	O
membranous	O
compartment	O
in	O
the	O
cells	B:C0007634
.	O

Thus	O
,	O
lipid	B:C0598783
metabolism	I:C0598783
modulators	O
are	O
good	O
candidates	O
to	O
regulate	O
virus	O
assembly	I:C0282629
and	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
replication	O
.	O

Thus	O
,	O
lipid	O
metabolism	I:C0598783
modulators	B:C1254351
are	O
good	O
candidates	O
to	O
regulate	O
virus	O
assembly	I:C0282629
and	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
replication	O
.	O

Thus	O
,	O
lipid	O
metabolism	I:C0598783
modulators	O
are	O
good	O
candidates	O
to	O
regulate	O
virus	B:C0282629
assembly	I:C0282629
and	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
replication	O
.	O

Thus	O
,	O
lipid	O
metabolism	I:C0598783
modulators	O
are	O
good	O
candidates	O
to	O
regulate	O
virus	O
assembly	I:C0282629
and	O
hepatitis	B:C0220847
C	I:C0220847
virus	I:C0220847
replication	O
.	O

Thus	O
,	O
lipid	O
metabolism	I:C0598783
modulators	O
are	O
good	O
candidates	O
to	O
regulate	O
virus	O
assembly	I:C0282629
and	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
replication	B:C0042774
.	O

Recent	O
studies	O
have	O
shown	O
that	O
stearoyl	B:C0038233
-	I:C0038233
CoA	I:C0038233
desaturase	I:C0038233
(	O
stearoyl	O
-	I:C0038233
CoA	I:C0038233
desaturase	I:C0038233
)	O
,	O
an	O
enzyme	O
for	O
long	O
-	I:C0015687
chain	I:C0015687
mono	I:C0015687
-	I:C0015687
unsaturated	I:C0015687
fatty	I:C0015687
acid	I:C0015687
(	O
long	O
-	I:C0015687
chain	I:C0015687
mono	I:C0015687
-	I:C0015687
unsaturated	I:C0015687
fatty	I:C0015687
acid	I:C0015687
)	O
synthesis	O
,	O
is	O
a	O
key	O
factor	O
that	O
defines	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
replication	O
efficiency	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
stearoyl	O
-	I:C0038233
CoA	I:C0038233
desaturase	I:C0038233
(	O
stearoyl	B:C0038233
-	I:C0038233
CoA	I:C0038233
desaturase	I:C0038233
)	O
,	O
an	O
enzyme	O
for	O
long	O
-	I:C0015687
chain	I:C0015687
mono	I:C0015687
-	I:C0015687
unsaturated	I:C0015687
fatty	I:C0015687
acid	I:C0015687
(	O
long	O
-	I:C0015687
chain	I:C0015687
mono	I:C0015687
-	I:C0015687
unsaturated	I:C0015687
fatty	I:C0015687
acid	I:C0015687
)	O
synthesis	O
,	O
is	O
a	O
key	O
factor	O
that	O
defines	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
replication	O
efficiency	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
stearoyl	O
-	I:C0038233
CoA	I:C0038233
desaturase	I:C0038233
(	O
stearoyl	O
-	I:C0038233
CoA	I:C0038233
desaturase	I:C0038233
)	O
,	O
an	O
enzyme	B:C0014442
for	O
long	O
-	I:C0015687
chain	I:C0015687
mono	I:C0015687
-	I:C0015687
unsaturated	I:C0015687
fatty	I:C0015687
acid	I:C0015687
(	O
long	O
-	I:C0015687
chain	I:C0015687
mono	I:C0015687
-	I:C0015687
unsaturated	I:C0015687
fatty	I:C0015687
acid	I:C0015687
)	O
synthesis	O
,	O
is	O
a	O
key	O
factor	O
that	O
defines	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
replication	O
efficiency	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
stearoyl	O
-	I:C0038233
CoA	I:C0038233
desaturase	I:C0038233
(	O
stearoyl	O
-	I:C0038233
CoA	I:C0038233
desaturase	I:C0038233
)	O
,	O
an	O
enzyme	O
for	O
long	B:C0015687
-	I:C0015687
chain	I:C0015687
mono	I:C0015687
-	I:C0015687
unsaturated	I:C0015687
fatty	I:C0015687
acid	I:C0015687
(	O
long	O
-	I:C0015687
chain	I:C0015687
mono	I:C0015687
-	I:C0015687
unsaturated	I:C0015687
fatty	I:C0015687
acid	I:C0015687
)	O
synthesis	O
,	O
is	O
a	O
key	O
factor	O
that	O
defines	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
replication	O
efficiency	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
stearoyl	O
-	I:C0038233
CoA	I:C0038233
desaturase	I:C0038233
(	O
stearoyl	O
-	I:C0038233
CoA	I:C0038233
desaturase	I:C0038233
)	O
,	O
an	O
enzyme	O
for	O
long	O
-	I:C0015687
chain	I:C0015687
mono	I:C0015687
-	I:C0015687
unsaturated	I:C0015687
fatty	I:C0015687
acid	I:C0015687
(	O
long	B:C0015687
-	I:C0015687
chain	I:C0015687
mono	I:C0015687
-	I:C0015687
unsaturated	I:C0015687
fatty	I:C0015687
acid	I:C0015687
)	O
synthesis	O
,	O
is	O
a	O
key	O
factor	O
that	O
defines	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
replication	O
efficiency	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
stearoyl	O
-	I:C0038233
CoA	I:C0038233
desaturase	I:C0038233
(	O
stearoyl	O
-	I:C0038233
CoA	I:C0038233
desaturase	I:C0038233
)	O
,	O
an	O
enzyme	O
for	O
long	O
-	I:C0015687
chain	I:C0015687
mono	I:C0015687
-	I:C0015687
unsaturated	I:C0015687
fatty	I:C0015687
acid	I:C0015687
(	O
long	O
-	I:C0015687
chain	I:C0015687
mono	I:C0015687
-	I:C0015687
unsaturated	I:C0015687
fatty	I:C0015687
acid	I:C0015687
)	O
synthesis	B:C0220781
,	O
is	O
a	O
key	O
factor	O
that	O
defines	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
replication	O
efficiency	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
stearoyl	O
-	I:C0038233
CoA	I:C0038233
desaturase	I:C0038233
(	O
stearoyl	O
-	I:C0038233
CoA	I:C0038233
desaturase	I:C0038233
)	O
,	O
an	O
enzyme	O
for	O
long	O
-	I:C0015687
chain	I:C0015687
mono	I:C0015687
-	I:C0015687
unsaturated	I:C0015687
fatty	I:C0015687
acid	I:C0015687
(	O
long	O
-	I:C0015687
chain	I:C0015687
mono	I:C0015687
-	I:C0015687
unsaturated	I:C0015687
fatty	I:C0015687
acid	I:C0015687
)	O
synthesis	O
,	O
is	O
a	O
key	O
factor	O
that	O
defines	O
hepatitis	B:C0220847
C	I:C0220847
virus	I:C0220847
replication	O
efficiency	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
stearoyl	O
-	I:C0038233
CoA	I:C0038233
desaturase	I:C0038233
(	O
stearoyl	O
-	I:C0038233
CoA	I:C0038233
desaturase	I:C0038233
)	O
,	O
an	O
enzyme	O
for	O
long	O
-	I:C0015687
chain	I:C0015687
mono	I:C0015687
-	I:C0015687
unsaturated	I:C0015687
fatty	I:C0015687
acid	I:C0015687
(	O
long	O
-	I:C0015687
chain	I:C0015687
mono	I:C0015687
-	I:C0015687
unsaturated	I:C0015687
fatty	I:C0015687
acid	I:C0015687
)	O
synthesis	O
,	O
is	O
a	O
key	O
factor	O
that	O
defines	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
replication	B:C0042774
efficiency	O
.	O

Systemic	O
exposure	O
to	O
SCD	B:C0038233
-	I:C0038233
1	I:C0038233
inhibor	O
induces	O
some	O
side	O
effects	I:C0041755
in	O
the	O
eyes	O
and	O
skin	O
.	O

Systemic	O
exposure	O
to	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibor	B:C0014432
induces	O
some	O
side	O
effects	I:C0041755
in	O
the	O
eyes	O
and	O
skin	O
.	O

Systemic	O
exposure	O
to	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibor	O
induces	O
some	O
side	B:C0041755
effects	I:C0041755
in	O
the	O
eyes	O
and	O
skin	O
.	O

Systemic	O
exposure	O
to	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibor	O
induces	O
some	O
side	O
effects	I:C0041755
in	O
the	O
eyes	B:C0015392
and	O
skin	O
.	O

Systemic	O
exposure	O
to	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibor	O
induces	O
some	O
side	O
effects	I:C0041755
in	O
the	O
eyes	O
and	O
skin	B:C1123023
.	O

Thus	O
,	O
systemic	O
SCD	B:C0038233
-	I:C0038233
1	I:C0038233
inhibitors	O
are	O
considered	O
inappropriate	O
for	O
hepatitis	O
C	I:C4288963
virus	I:C4288963
therapy	O
.	O

Thus	O
,	O
systemic	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	B:C0014432
are	O
considered	O
inappropriate	O
for	O
hepatitis	O
C	I:C4288963
virus	I:C4288963
therapy	O
.	O

Thus	O
,	O
systemic	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	O
are	O
considered	O
inappropriate	O
for	O
hepatitis	B:C4288963
C	I:C4288963
virus	I:C4288963
therapy	O
.	O

To	O
avoid	O
the	O
side	B:C0041755
effects	I:C0041755
of	O
systemic	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	O
,	O
the	O
liver	O
-	O
specific	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitor	O
,	O
MK8245	O
,	O
was	O
synthesized	O
;	O
it	O
showed	O
antidiabetic	O
effects	I:C0243095
in	O
diabetic	O
model	O
mice	I:C0025929
with	O
no	O
side	O
effects	I:C0041755
.	O

To	O
avoid	O
the	O
side	O
effects	I:C0041755
of	O
systemic	O
SCD	B:C0038233
-	I:C0038233
1	I:C0038233
inhibitors	O
,	O
the	O
liver	O
-	O
specific	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitor	O
,	O
MK8245	O
,	O
was	O
synthesized	O
;	O
it	O
showed	O
antidiabetic	O
effects	I:C0243095
in	O
diabetic	O
model	O
mice	I:C0025929
with	O
no	O
side	O
effects	I:C0041755
.	O

To	O
avoid	O
the	O
side	O
effects	I:C0041755
of	O
systemic	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	B:C0014432
,	O
the	O
liver	O
-	O
specific	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitor	O
,	O
MK8245	O
,	O
was	O
synthesized	O
;	O
it	O
showed	O
antidiabetic	O
effects	I:C0243095
in	O
diabetic	O
model	O
mice	I:C0025929
with	O
no	O
side	O
effects	I:C0041755
.	O

To	O
avoid	O
the	O
side	O
effects	I:C0041755
of	O
systemic	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	O
,	O
the	O
liver	B:C0023884
-	O
specific	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitor	O
,	O
MK8245	O
,	O
was	O
synthesized	O
;	O
it	O
showed	O
antidiabetic	O
effects	I:C0243095
in	O
diabetic	O
model	O
mice	I:C0025929
with	O
no	O
side	O
effects	I:C0041755
.	O

To	O
avoid	O
the	O
side	O
effects	I:C0041755
of	O
systemic	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	O
,	O
the	O
liver	O
-	O
specific	O
SCD	B:C0038233
-	I:C0038233
1	I:C0038233
inhibitor	O
,	O
MK8245	O
,	O
was	O
synthesized	O
;	O
it	O
showed	O
antidiabetic	O
effects	I:C0243095
in	O
diabetic	O
model	O
mice	I:C0025929
with	O
no	O
side	O
effects	I:C0041755
.	O

To	O
avoid	O
the	O
side	O
effects	I:C0041755
of	O
systemic	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	O
,	O
the	O
liver	O
-	O
specific	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitor	B:C0014432
,	O
MK8245	O
,	O
was	O
synthesized	O
;	O
it	O
showed	O
antidiabetic	O
effects	I:C0243095
in	O
diabetic	O
model	O
mice	I:C0025929
with	O
no	O
side	O
effects	I:C0041755
.	O

To	O
avoid	O
the	O
side	O
effects	I:C0041755
of	O
systemic	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	O
,	O
the	O
liver	O
-	O
specific	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitor	O
,	O
MK8245	B:C3252063
,	O
was	O
synthesized	O
;	O
it	O
showed	O
antidiabetic	O
effects	I:C0243095
in	O
diabetic	O
model	O
mice	I:C0025929
with	O
no	O
side	O
effects	I:C0041755
.	O

To	O
avoid	O
the	O
side	O
effects	I:C0041755
of	O
systemic	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	O
,	O
the	O
liver	O
-	O
specific	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitor	O
,	O
MK8245	O
,	O
was	O
synthesized	O
;	O
it	O
showed	O
antidiabetic	B:C0243095
effects	I:C0243095
in	O
diabetic	O
model	O
mice	I:C0025929
with	O
no	O
side	O
effects	I:C0041755
.	O

To	O
avoid	O
the	O
side	O
effects	I:C0041755
of	O
systemic	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	O
,	O
the	O
liver	O
-	O
specific	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitor	O
,	O
MK8245	O
,	O
was	O
synthesized	O
;	O
it	O
showed	O
antidiabetic	O
effects	I:C0243095
in	O
diabetic	B:C0241863
model	O
mice	I:C0025929
with	O
no	O
side	O
effects	I:C0041755
.	O

To	O
avoid	O
the	O
side	O
effects	I:C0041755
of	O
systemic	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	O
,	O
the	O
liver	O
-	O
specific	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitor	O
,	O
MK8245	O
,	O
was	O
synthesized	O
;	O
it	O
showed	O
antidiabetic	O
effects	I:C0243095
in	O
diabetic	O
model	B:C0025929
mice	I:C0025929
with	O
no	O
side	O
effects	I:C0041755
.	O

To	O
avoid	O
the	O
side	O
effects	I:C0041755
of	O
systemic	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	O
,	O
the	O
liver	O
-	O
specific	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitor	O
,	O
MK8245	O
,	O
was	O
synthesized	O
;	O
it	O
showed	O
antidiabetic	O
effects	I:C0243095
in	O
diabetic	O
model	O
mice	I:C0025929
with	O
no	B:C1513916
side	O
effects	I:C0041755
.	O

To	O
avoid	O
the	O
side	O
effects	I:C0041755
of	O
systemic	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	O
,	O
the	O
liver	O
-	O
specific	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitor	O
,	O
MK8245	O
,	O
was	O
synthesized	O
;	O
it	O
showed	O
antidiabetic	O
effects	I:C0243095
in	O
diabetic	O
model	O
mice	I:C0025929
with	O
no	O
side	B:C0041755
effects	I:C0041755
.	O

In	O
the	O
phase	O
1	O
clinical	B:C0008972
study	I:C0008972
on	O
measurement	O
of	O
MK8245	O
tolerability	O
,	O
no	O
significant	I:C1273937
side	O
effects	I:C0041755
were	O
reported	O
(	O
ClinicalTrials.gov	O
Identifier	O
:	O
NCT00790556	O
)	O
.	O

In	O
the	O
phase	O
1	O
clinical	O
study	I:C0008972
on	O
measurement	O
of	O
MK8245	B:C3252063
tolerability	O
,	O
no	O
significant	I:C1273937
side	O
effects	I:C0041755
were	O
reported	O
(	O
ClinicalTrials.gov	O
Identifier	O
:	O
NCT00790556	O
)	O
.	O

In	O
the	O
phase	O
1	O
clinical	O
study	I:C0008972
on	O
measurement	O
of	O
MK8245	O
tolerability	B:C3274448
,	O
no	O
significant	I:C1273937
side	O
effects	I:C0041755
were	O
reported	O
(	O
ClinicalTrials.gov	O
Identifier	O
:	O
NCT00790556	O
)	O
.	O

In	O
the	O
phase	O
1	O
clinical	O
study	I:C0008972
on	O
measurement	O
of	O
MK8245	O
tolerability	O
,	O
no	B:C1273937
significant	I:C1273937
side	O
effects	I:C0041755
were	O
reported	O
(	O
ClinicalTrials.gov	O
Identifier	O
:	O
NCT00790556	O
)	O
.	O

In	O
the	O
phase	O
1	O
clinical	O
study	I:C0008972
on	O
measurement	O
of	O
MK8245	O
tolerability	O
,	O
no	O
significant	I:C1273937
side	B:C0041755
effects	I:C0041755
were	O
reported	O
(	O
ClinicalTrials.gov	O
Identifier	O
:	O
NCT00790556	O
)	O
.	O

In	O
the	O
phase	O
1	O
clinical	O
study	I:C0008972
on	O
measurement	O
of	O
MK8245	O
tolerability	O
,	O
no	O
significant	I:C1273937
side	O
effects	I:C0041755
were	O
reported	O
(	O
ClinicalTrials.gov	B:C4086204
Identifier	O
:	O
NCT00790556	O
)	O
.	O

Therefore	O
,	O
we	O
thought	O
liver	B:C0023884
-	O
specific	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	O
would	O
be	O
suitable	O
agents	O
for	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
-	O
infected	O
patients	O
.	O

Therefore	O
,	O
we	O
thought	O
liver	O
-	O
specific	O
SCD	B:C0038233
-	I:C0038233
1	I:C0038233
inhibitors	O
would	O
be	O
suitable	O
agents	O
for	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
-	O
infected	O
patients	O
.	O

Therefore	O
,	O
we	O
thought	O
liver	O
-	O
specific	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	B:C0014432
would	O
be	O
suitable	O
agents	O
for	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
-	O
infected	O
patients	O
.	O

Therefore	O
,	O
we	O
thought	O
liver	O
-	O
specific	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	O
would	O
be	O
suitable	O
agents	B:C1254351
for	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
-	O
infected	O
patients	O
.	O

Therefore	O
,	O
we	O
thought	O
liver	O
-	O
specific	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	O
would	O
be	O
suitable	O
agents	O
for	O
hepatitis	B:C0220847
C	I:C0220847
virus	I:C0220847
-	O
infected	O
patients	O
.	O

Therefore	O
,	O
we	O
thought	O
liver	O
-	O
specific	O
SCD	O
-	I:C0038233
1	I:C0038233
inhibitors	O
would	O
be	O
suitable	O
agents	O
for	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
-	O
infected	B:C0439663
patients	O
.	O

MK8245	B:C3252063
was	O
evaluated	O
using	O
recombinant	O
HCV	O
culture	O
systems	I:C1516329
.	O

MK8245	O
was	O
evaluated	O
using	O
recombinant	O
HCV	O
culture	B:C1516329
systems	I:C1516329
.	O

Considering	O
current	O
hepatitis	B:C0220847
C	I:C0220847
virus	I:C0220847
treatments	O
,	O
to	O
avoid	O
the	O
emergence	O
of	O
direct	O
anti-viral	O
agents	I:C0003451
-	O
resistant	O
viruses	O
,	O
combination	O
therapy	I:C0009429
with	O
direct	O
anti-viral	O
agents	I:C0003451
and	O
host	O
-	O
targeted	O
agents	O
would	O
be	O
optimal	O
.	O

Considering	O
current	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
treatments	B:C0087111
,	O
to	O
avoid	O
the	O
emergence	O
of	O
direct	O
anti-viral	O
agents	I:C0003451
-	O
resistant	O
viruses	O
,	O
combination	O
therapy	I:C0009429
with	O
direct	O
anti-viral	O
agents	I:C0003451
and	O
host	O
-	O
targeted	O
agents	O
would	O
be	O
optimal	O
.	O

Considering	O
current	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
treatments	O
,	O
to	O
avoid	O
the	O
emergence	O
of	O
direct	O
anti-viral	B:C0003451
agents	I:C0003451
-	O
resistant	O
viruses	O
,	O
combination	O
therapy	I:C0009429
with	O
direct	O
anti-viral	O
agents	I:C0003451
and	O
host	O
-	O
targeted	O
agents	O
would	O
be	O
optimal	O
.	O

Considering	O
current	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
treatments	O
,	O
to	O
avoid	O
the	O
emergence	O
of	O
direct	O
anti-viral	O
agents	I:C0003451
-	O
resistant	O
viruses	B:C0042776
,	O
combination	O
therapy	I:C0009429
with	O
direct	O
anti-viral	O
agents	I:C0003451
and	O
host	O
-	O
targeted	O
agents	O
would	O
be	O
optimal	O
.	O

Considering	O
current	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
treatments	O
,	O
to	O
avoid	O
the	O
emergence	O
of	O
direct	O
anti-viral	O
agents	I:C0003451
-	O
resistant	O
viruses	O
,	O
combination	B:C0009429
therapy	I:C0009429
with	O
direct	O
anti-viral	O
agents	I:C0003451
and	O
host	O
-	O
targeted	O
agents	O
would	O
be	O
optimal	O
.	O

Considering	O
current	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
treatments	O
,	O
to	O
avoid	O
the	O
emergence	O
of	O
direct	O
anti-viral	O
agents	I:C0003451
-	O
resistant	O
viruses	O
,	O
combination	O
therapy	I:C0009429
with	O
direct	O
anti-viral	B:C0003451
agents	I:C0003451
and	O
host	O
-	O
targeted	O
agents	O
would	O
be	O
optimal	O
.	O

Considering	O
current	O
hepatitis	O
C	I:C0220847
virus	I:C0220847
treatments	O
,	O
to	O
avoid	O
the	O
emergence	O
of	O
direct	O
anti-viral	O
agents	I:C0003451
-	O
resistant	O
viruses	O
,	O
combination	O
therapy	I:C0009429
with	O
direct	O
anti-viral	O
agents	I:C0003451
and	O
host	O
-	O
targeted	O
agents	B:C1254351
would	O
be	O
optimal	O
.	O

With	O
this	O
viewpoint	O
,	O
we	O
confirmed	O
MK8245	B:C3252063
's	O
additive	O
or	O
synergistic	O
anti-HCV	O
effects	I:C0243095
on	O
current	O
direct	O
anti-viral	O
agents	I:C0003451
and	O
interferon	O
-	I:C0854621
alpha	I:C0854621
therapy	I:C0854621
.	O

With	O
this	O
viewpoint	O
,	O
we	O
confirmed	O
MK8245	O
's	O
additive	O
or	O
synergistic	O
anti-HCV	B:C0243095
effects	I:C0243095
on	O
current	O
direct	O
anti-viral	O
agents	I:C0003451
and	O
interferon	O
-	I:C0854621
alpha	I:C0854621
therapy	I:C0854621
.	O

With	O
this	O
viewpoint	O
,	O
we	O
confirmed	O
MK8245	O
's	O
additive	O
or	O
synergistic	O
anti-HCV	O
effects	I:C0243095
on	O
current	O
direct	O
anti-viral	B:C0003451
agents	I:C0003451
and	O
interferon	O
-	I:C0854621
alpha	I:C0854621
therapy	I:C0854621
.	O

With	O
this	O
viewpoint	O
,	O
we	O
confirmed	O
MK8245	O
's	O
additive	O
or	O
synergistic	O
anti-HCV	O
effects	I:C0243095
on	O
current	O
direct	O
anti-viral	O
agents	I:C0003451
and	O
interferon	B:C0854621
-	I:C0854621
alpha	I:C0854621
therapy	I:C0854621
.	O

The	O
results	O
suggest	O
that	O
MK8245	B:C3252063
is	O
an	O
option	O
for	O
anti-HCV	O
multi-	O
drug	I:C0013216
therapy	I:C0013216
with	O
a	O
low	O
risk	O
of	O
emergence	O
of	O
drug	O
-	I:C0013203
resistant	I:C0013203
hepatitis	O
C	I:C0220847
virus	I:C0220847
without	O
significant	O
side	O
effects	I:C0041755
.	O

The	O
results	O
suggest	O
that	O
MK8245	O
is	O
an	O
option	O
for	O
anti-HCV	B:C0243095
multi-	O
drug	I:C0013216
therapy	I:C0013216
with	O
a	O
low	O
risk	O
of	O
emergence	O
of	O
drug	O
-	I:C0013203
resistant	I:C0013203
hepatitis	O
C	I:C0220847
virus	I:C0220847
without	O
significant	O
side	O
effects	I:C0041755
.	O

The	O
results	O
suggest	O
that	O
MK8245	O
is	O
an	O
option	O
for	O
anti-HCV	O
multi-	B:C0013216
drug	I:C0013216
therapy	I:C0013216
with	O
a	O
low	O
risk	O
of	O
emergence	O
of	O
drug	O
-	I:C0013203
resistant	I:C0013203
hepatitis	O
C	I:C0220847
virus	I:C0220847
without	O
significant	O
side	O
effects	I:C0041755
.	O

The	O
results	O
suggest	O
that	O
MK8245	O
is	O
an	O
option	O
for	O
anti-HCV	O
multi-	O
drug	I:C0013216
therapy	I:C0013216
with	O
a	O
low	O
risk	O
of	O
emergence	O
of	O
drug	B:C0013203
-	I:C0013203
resistant	I:C0013203
hepatitis	O
C	I:C0220847
virus	I:C0220847
without	O
significant	O
side	O
effects	I:C0041755
.	O

The	O
results	O
suggest	O
that	O
MK8245	O
is	O
an	O
option	O
for	O
anti-HCV	O
multi-	O
drug	I:C0013216
therapy	I:C0013216
with	O
a	O
low	O
risk	O
of	O
emergence	O
of	O
drug	O
-	I:C0013203
resistant	I:C0013203
hepatitis	B:C0220847
C	I:C0220847
virus	I:C0220847
without	O
significant	O
side	O
effects	I:C0041755
.	O

The	O
results	O
suggest	O
that	O
MK8245	O
is	O
an	O
option	O
for	O
anti-HCV	O
multi-	O
drug	I:C0013216
therapy	I:C0013216
with	O
a	O
low	O
risk	O
of	O
emergence	O
of	O
drug	O
-	I:C0013203
resistant	I:C0013203
hepatitis	O
C	I:C0220847
virus	I:C0220847
without	O
significant	O
side	B:C0041755
effects	I:C0041755
.	O

